Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07613684 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants
A Phase 1 study, sponsored by Epirium Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT07613684: Completed Phase 1 study, sponsored by Epirium Bio.
NCT07613684 is a Phase 1 study that has completed, run by Epirium Bio. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07613684, a Phase 1 study, has completed, sponsored by Epirium Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) healthy adult subjects.
Primary Outcome
Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment
Interventions
- DRUG Placebo
- DRUG MF-300 SAD
- DRUG MF-300 Food Effect
- DRUG MF-300 MAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 1 |
What the finished NCT07613684 record still lists
NCT07613684 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07613684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07613684 about?
NCT07613684 is a clinical study titled "Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants". The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) he...
What is the current status of trial NCT07613684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-12-20. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT07613684?
The interventions under investigation include: Placebo (DRUG), MF-300 SAD (DRUG), MF-300 Food Effect (DRUG), MF-300 MAD (DRUG).
Who is sponsoring clinical trial NCT07613684?
This trial is sponsored by Epirium Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07613684's enrollment target sits among peer trials
100 546th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI